The U.S. Food and Drug Administration (FDA) recently approved Hemlibra (Emicizumab), a new subcutaneous treatment for hemophilia A with or without inhibitors. To help the bleeding disorders community better understand this therapy, on Tuesday, November 20th, the Boston Hemophilia Center and the New England Hemophilia Association (NEHA) hosted an educational webinar about the pros and cons of Hemlibra (Emicizumab). Presenters on the webinar are Stacy E. Croteau, MD, MMS Pediatric Hematologist, and Aric Parnes, MD, Adult Hematologist at the Boston Hemophilia Center.
Негізгі бет Webinar: Pros & Cons of Hemlibra Therapy for Hemophilia
No video
Пікірлер: 7